Under terms of the deal, Stoke will spearhead global development of zorevunersen, while Biogen will receive exclusive rights ...

Ionis relies on upfront payments and licensing fees from partners, as well as Spinraza royalties, to drive revenue today, but its rapidly advancing portfolio should help diversify revenue. 2025 is ...

Biogen and Stoke Therapeutics have announced a partnership aimed at advancing a disease-modifying treatment for Dravet ...

Stoke Therapeutics (NASDAQ:STOK – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at Needham & Company LLC in a research note issued on Tuesday,Benzinga reports. They presently ...

Stoke Therapeutics (NASDAQ:STOK – Get Free Report) had its target price raised by analysts at HC Wainwright from $35.00 to $47.00 in a research note issued on Tuesday,Benzinga reports. The firm ...

During Q4, Ionis reported revenues of $227 million, 68.1% above the $135 million estimated by analysts. That positive surprise was attributed in part to the successful launch and commercialization of ...

Biogen will receive rights to commercialize zorevunersen outside the US, Canada, and Mexico, paying $165 million upfront and other milestone payments.

Biogen receives exclusive rights to commercialize zorevunersen outside U.S., Europe, and Japan.

Market OverviewThe Global RNA Therapeutics Market is valued at USD 13.3 Billion in 2023 and is projected to reach a value ...

Biogen has bolstered its pipeline by licensing ex-US rights to a drug for Dravet syndrome – a rare form of epilepsy – from ...

Biogen has entered a collaboration with Stoke Therapeutics to develop and and commercialise zorevunersen to treat Dravet ...

Biogen and Stoke partner on zorevunersen for Dravet syndrome, with a Phase 3 trial starting in 2025. Stoke gets $165 million ...